Subantimicrobial Dose Doxycycline Enhances the Efficacy of Scaling and Root Planing in Chronic Periodontitis: A Multicenter Trial

Preshaw, Philip M.; Hefti, Arthur F.; Novak, M. John; Michalowicz, Bryan S.; Pihlstrom, Bruce Lee; Schoor, Robert; Trummel, Clarence L.; Dean, John W.; Dyke, Thomas E. Van; Walker, Clay; Bradshaw, Mark

doi:10.1902/jop.2004.75.8.1068

Cited by 96 publications

(124 citation statements)

References 25 publications

Supporting

Mentioning

107

Contrasting

Unclassified

Order By: Relevance

“…Currently, however, the only FDA-approved MMP inhibitor is the tetracycline analogue doxycycline (Periostat Õ ) for the treatment of periodontal disease. [289][290][291] The major obstacle hindering the development of MMP inhibitors for clinical use in patients is our lack of knowledge and understanding of the complex MMP biology and the role MMPs play in CNS disorders such as cerebral aneurysm, epilepsy, AD, and PD. Nonetheless, there is a wealth of preclinical data that support MMP inhibition as a treatment strategy in MS, stroke, and brain cancer.…”

Section: Mmp Inhibition As a Therapeutic Strategymentioning

confidence: 99%

Matrix metalloproteinases in the brain and blood–brain barrier: Versatile breakers and makers

Rempe

Hartz

Bauer

2016

J Cereb Blood Flow Metab

493

422

View full text Add to dashboard Cite

Matrix metalloproteinases are versatile endopeptidases with many different functions in the body in health and disease. In the brain, matrix metalloproteinases are critical for tissue formation, neuronal network remodeling, and blood-brain barrier integrity. Many reviews have been published on matrix metalloproteinases before, most of which focus on the two best studied matrix metalloproteinases, the gelatinases MMP-2 and MMP-9, and their role in one or two diseases. In this review, we provide a broad overview of the role various matrix metalloproteinases play in brain disorders. We summarize and review current knowledge and understanding of matrix metalloproteinases in the brain and at the bloodbrain barrier in neuroinflammation, multiple sclerosis, cerebral aneurysms, stroke, epilepsy, Alzheimer's disease, Parkinson's disease, and brain cancer. We discuss the detrimental effects matrix metalloproteinases can have in these conditions, contributing to blood-brain barrier leakage, neuroinflammation, neurotoxicity, demyelination, tumor angiogenesis, and cancer metastasis. We also discuss the beneficial role matrix metalloproteinases can play in neuroprotection and anti-inflammation. Finally, we address matrix metalloproteinases as potential therapeutic targets. Together, in this comprehensive review, we summarize current understanding and knowledge of matrix metalloproteinases in the brain and at the blood-brain barrier in brain disorders.

show abstract

Section: Mmp Inhibition As a Therapeutic Strategymentioning

confidence: 99%

Matrix metalloproteinases in the brain and blood–brain barrier: Versatile breakers and makers

Rempe

Hartz

Bauer

2016

J Cereb Blood Flow Metab

493

422

View full text Add to dashboard Cite

show abstract

“…Additionally, SDD inhibits the activation of MMPs precursors [10]. SDD has high affinity to bone and soft tissues, thus, its accumulation in the periodontium would further enhance its curative effect [15]. Chio et al [8] reported similar results after administration of SDD that was associated with significant decrease in MMP-8 level in their patients' GCF.…”

Section: Discussionmentioning

confidence: 97%

“…SDD has been used as an adjunct to standardscaling and root planning (SRP) for the management of periodontal diseases for different treatment periods. Some studies declared significant improvements over those achieved by standard scaling alone [14,15]. Moreover, the long-term use of SDD has been shown to be safe and not associated with the development of antibiotic resistance in the periodontal microbial flora [16].…”

Section: Introductionmentioning

confidence: 99%

Doxycycline and Coenzyme Q10 Treatment Modalities for Chronic Periodontitis: A Preliminary Study

Darweesh¹,

El-Sharkawy²,

Fadhil³

et al. 2015

Int J Oral Dent Health

View full text Add to dashboard Cite

“…[15][16][17] Therefore, the aim of this review was to compare the effects of adjunctive use of NSAIDs with nonsurgical periodontal treatment (NSPT) on periodontal disease based on the available literature. Following focused question was addressed: "In patients with periodontal disease, is there an additional benefit of the oral administration of NSAIDs adjunctive with NSPT compared to control in terms of the clinical attachment level (CAL), probing depth (PD), and adverse outcomes in randomized controlled trials?…”

Section: Introductionmentioning

confidence: 99%

Effects of host modulation by nonsteroidal anti-inflammatory drugs on periodontal disease: a systematic review and meta-analysis

Kang

Cho

Shin

et al. 2017

J Dent Rehabil Appl Sci

View full text Add to dashboard Cite

Purpose: Nonsteroidal anti-inflammatory drugs that prohibit biosynthesis of arachidonic acid metabolites have been considered potent host modulation agents. The aim of this review was to determine the effect of nonsteroidal anti-inflammatory drugs adjunctive with nonsurgical periodontal treatment in patients with periodontal disease. Materials and Methods: Three electronic databases were searched to identify relevant studies. The methodological quality and mean differences of the change in clinical attachment level and probing depth were analyzed according to Cochrane review methods. Results: Twelve studies were included in the methodological assessment and nine studies were suitable for inclusion in the meta-analysis. The mean difference in the clinical attachment level gain did not differ significantly between the nonsteroidal anti-inflammatory drugs and control groups at any observation time. The highest mean difference in clinical attachment level gain was 0.30 mm at 4 weeks (95% confidence interval = -0.37 to 0.97). There was a significant mean difference in the probing depth reduction, of 0.34 mm (95% confidence interval = 0.29 to 0.40) at 6 weeks. Conclusion: Therefore, nonsteroidal anti-inflammatory drugs have additional therapeutic effect when administrated with nonsurgical periodontal treatment.

show abstract

Subantimicrobial Dose Doxycycline Enhances the Efficacy of Scaling and Root Planing in Chronic Periodontitis: A Multicenter Trial

Abstract: Adjunctive subantimicrobial dose doxycycline enhances scaling and root planing. It results in statistically significant attachment gains and probing depth reductions over and above those achieved by scaling and root planing with placebo.

Cited by 96 publications

References 25 publications

Matrix metalloproteinases in the brain and blood–brain barrier: Versatile breakers and makers

Matrix metalloproteinases in the brain and blood–brain barrier: Versatile breakers and makers

Doxycycline and Coenzyme Q10 Treatment Modalities for Chronic Periodontitis: A Preliminary Study

Effects of host modulation by nonsteroidal anti-inflammatory drugs on periodontal disease: a systematic review and meta-analysis

Contact Info

Product

Resources

About